IL-17 Receptor inhibition with brodalumab limits experimental periodontitis Authors: Araceli Valverde, Raza Ali Naqvi, Matt Tokarski, Kristofer Ceredon, Joseph Gluck, Sarah Elshourbagy, Gloria Martínez, Maria Brambilla, Salvador Nares, Joel Schwartz, Afsar R Naqvi Published: 2026 ABSTRACT AbstractBackgroundPeriodontal disease (PD) is a chronic, biofilm-driven inflammatory condition in which connective tissue destruction and alveolar bone loss are driven largely by dysregulated host immunity. Prior experimental and clinical studies have linked IL-17 pathway activity to periodontal inflammation and treatment response, supporting its relevance as a therapeutic target in PD. Rather than targeting individual IL-17 isoforms, IL-17R blockade offers an alternative strategy because it serves as a shared downstream signaling node for multiple IL-17 family cytokines, potentially enabling broader modulation of inflammatory signaling. However, the therapeutic potential of IL-17R blockade in PD remains largely unexplored.MethodsGingival and salivary immune profiles and inflammatory markers were assessed in periodontally healthy, diseased, and post-therapy subjects. For mechanistic studies, mice subjected to ligature-induced periodontitis (LIP) received local gingival injection of the IL-17 receptor inhibitor brodalumab at 5 or 20 mg/kg, or vehicle control every 48 h. Animals were euthanized on day 4 or day 8 post-treatment, and gingival inflammatory responses were quantified by qPCR and flow cytometry. Alveolar bone outcomes were assessed by micro-CT, including CEJ–ABC distance as a measure of bone loss, and bone volume and bone mineral density as measures of bone quality.ResultsGingival and salivary CD4⁺IL-17⁺ T cells were increased in PD and were markedly reduced after therapy, supporting the association of IL-17-driven immune responses with disease activity and their resolution following treatment. This observation was validated in human gingival biopsies, where IL-17 expression was elevated in PD and markedly reduced after nonsurgical periodontal therapy, accompanied by lower inflammatory cytokine expression and a shift toward a healthy control profile. In LIP mice, local injection of brodalumab reduced gingival inflammatory transcripts, with IL-17A suppressed by day 4 and sustained through day 8, alongside reduced IL-17B, indicating broader dampening of IL-17 signaling. These changes were associated with reduced gingival neutrophil infiltration and M2-like macrophage skewing, indicating that brodalumab promotes the resolution of inflammation. Micro-CT demonstrated lower alveolar bone loss in a dose-dependent manner in brodalumab treated animals. Brodalumab also preserved bone quality, increasing bone volume and bone mineral density, most prominently at the higher dose, which approached no-ligature values by day 8.ConclusionLocal gingival administration of brodalumab attenuates IL-17–associated inflammatory responses and protects against alveolar bone loss in experimental periodontitis. Our findings support IL-17R blockade as a promising host-modulatory strategy that could serve as an adjunct to conventional periodontal care to limit periodontal tissue destruction.Keywords: Periodontitis, IL-17/IL-17R signaling, Brodalumab, Alveolar bone loss, Resolution Introduction Periodontal disease (PD) is a chronic, biofilm-driven inflammatory condition that leads to destruction of the tooth-supporting tissues, including gingiva, periodontal ligament, and alveolar bone tissues [1, 2]. While the initiating trigger is a dysbiotic oral microbial community, tissue breakdown in PD is largely mediated by an exaggerated or unresolved host immune response rather than direct bacterial toxicity [1, 3]. Current standard-of-care therapy focuses on mechanical disruption of the biofilm and risk factor control [4, 5]; however, a subset of patients continues to exhibit progressive disease [6], highlighting a need for host-modulatory strategies that complement conventional periodontal treatment. There have been repeated efforts diverse approaches to suppress gingival inflammation using diverse approaches, including flavonoids, C3-complement inhibition, targeted immunotherapies (e.g., anti-CD20, anti-IL-6R), bone-modulatory strategies such as specialized pro-resolving mediators (SPMs), and manipulation of the oral microbiome [7–10]. Previous studies have demonstrated that targeting upstream inflammatory mediators can effectively attenuate periodontal inflammation and alveolar bone loss [11, 12]. For example, inhibition of the NLRP3 inflammasome with MCC950 significantly reduced IL-1β production, suppressed osteoclastogenesis, and decreased alveolar bone loss in experimental periodontitis, highlighting the critical role of IL-1β-driven inflammatory pathways in periodontal tissue destruction [13]. Likewise, pharmacological inhibition of TNF-α using pentoxifylline or thalidomide significantly reduced inflammatory cell infiltration and alveolar bone resorption in ligature-induced periodontitis models [14]. Collectively, these findings support the concept that modulation of key pro-inflammatory cytokines and their upstream regulators represents a promising host-modulatory strategy for periodontitis. Nevertheless, the complex network of cytokine interactions involved in periodontal disease progression suggests that additional inflammatory pathways may contribute to immune dysregulation, persistent inflammation, and tissue destruction. One such pathway is mediated by the interleukin-17 (IL-17) family, which has emerged as an important driver of mucosal inflammation and bone-destructive responses [15, 16]. IL-17A, commonly referred to as IL-17, is a pro-inflammatory cytokine produced by several immune subsets, most prominently T helper 17 (Th17) cells, but also γδ T cells, innate lymphoid cells, and neutrophil-associated sources in inflamed tissues, which are central to the development of periodontitis [15–17]. In PD, elevated IL-17 signatures have been reported in gingival tissues and oral fluids, and IL-17–driven responses are linked to persistent inflammation, dysregulated neutrophil trafficking, and osteoclastogenic signaling that can accelerate alveolar bone loss. Th17-derived interleukin-17 can mediate bone immunopathology by inducing matrix metalloproteinases (MMPs) and Receptor Activator of Nuclear factor kappa beta Ligand (RANKL) [18–20], thereby contributing to the degradation of both connective tissue and the underlying alveolar bone in both human periodontitis and experimental periodontitis in animal models. Furthermore, recent observations that the inhibition of RANKL expression by Complement inhibitor Cp40 in non-human primate periodontitis may, in part, be attributed to the ability of this C3 inhibitor to suppress IL-17 production [21, 22]. These observations support the concept that IL-17 does not merely mark inflammation in PD but can actively sustain pathogenic immune circuits within the periodontal environment. Evidence from both human and experimental studies supports IL-17 as a contributor to periodontal inflammation and alveolar bone loss and has motivated interest in therapeutic modulation of this pathway [23]. However, IL-17 biology in periodontitis appears stage-dependent in animal models, with IL-17 promoting bone loss early but showing a more protective association later, suggesting timing may be critical for IL-17–pathway intervention [24]. IL-17 family cytokines initiate and amplify inflammatory signaling pathways that are shared across diverse autoimmune and inflammatory disorders [15, 17, 25]. These mechanistic insights highlight IL-17 as a pivotal driver of disease pathobiology, providing a rationale for strategies aimed at modulating this pathogenic signaling. Preclinical studies demonstrate that IL-17 is a critical mediator of alveolar bone loss in murine periodontitis, driving neutrophil infiltration and upregulating pro-inflammatory cytokines [23]. Targeted anti-IL-17 therapy effectively suppresses gingival inflammation, reduces osteoclast activity, and downregulates IL-6 and TNF-α expression, underscoring IL-17 as a key therapeutic target in periodontal disease [26–28]. While not yet part of standard care for periodontitis, emerging evidence suggests that modulation of IL-17 may help limit inflammation and tissue destruction in susceptible patients, particularly those with comorbid autoimmune conditions. Given these shared pathogenic mechanisms, anti–IL-17 therapy represents a promising strategy for systemic autoimmune diseases and may also have potential in severe periodontal disease. However, selectively targeting individual IL-17 isoforms remain challenging due to functional redundancy within the IL-17 family, as multiple isoforms can activate overlapping inflammatory pathways. IL-17 biology is defined by a shared receptor architecture, allowing multiple family cytokines, including IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (IL-25), and IL-17F [25], to signal through a common pathway. The IL-17 receptor family (IL-17RA–IL-17RE) is widely expressed, with IL-17RA serving as the central hub, forming heterodimers that activate downstream pro-inflammatory gene expression [15, 16, 28–30]. Targeting IL-17RA offers broader suppression of IL-17–driven inflammation than ligand-specific inhibition [15, 16, 31]. Brodalumab, a human IL-17RA antagonist, blocks IL-17A and IL-17F signaling and is expressed in gingival keratinocytes, endothelial cells, lymphocytes, fibroblasts, lung tissue, myelomonocytic cells, and bone marrow, with robust signaling via IL-17RA/IL-17RC complexes, with similar responses for IL-17RA/IL-17RB [32–36]. Soluble receptor isoforms from alternative splicing can modulate activity in various tissues [36]. Clinically, IL-17RA blockade is validated in immune-mediated diseases, with FDA-approved brodalumab demonstrating efficacy in psoriasis [37, 38]. Despite the strong mechanistic rationale for IL-17RA blockade in inflammatory settings, IL-17RA-targeted therapy has not been specifically evaluated in PD, where the inflammatory lesion is localized and accessible for targeted intervention. Given the evidence implicating IL-17 pathways in periodontal immunopathology [13, 14], assessing IL-17RA blockade in PD is timely and could inform the development of adjunctive, host-directed therapies aimed at controlling inflammation and limiting bone loss. This study repurposed brodalumab using a murine model of periodontitis and demonstrated that local drug delivery reduced IL-17-driven gingival inflammation, shifted T cells toward regulatory T cells Tregs, and prevented ligature-induced alveolar bone loss. Materials and methods Ethical approval This study was conducted in accordance with the Declaration of Helsinki. Protocols were approved by the Ethics Committee at the Institutional Review Board at the University of Illinois at Chicago, College of Dentistry (IRB #2017 − 1064; IRB #2016 − 0696). Written informed consent was obtained from all participants, and HIPAA guidelines were followed to ensure confidentiality. Human subjects Systemically healthy subjects aged 18–70 years presenting to the Postgraduate Periodontics Clinic at the College of Dentistry, University of Illinois Chicago, from March 2022 to May 2025 were recruited for this study. These 20 individuals were divided into two groups: periodontally healthy (Healthy Control; n = 10) and Stage III, Grade B periodontitis (Experimental, Diseased; n = 10). Individuals were excluded if they presented with uncontrolled systemic disorders: hypertension, heart disease, bleeding disorders, were pregnant, diabetic, current smokers, or presented with oral pathologies other than periodontal disease. Subjects in the periodontally healthy group presented with probing depths (PD) ≤ 3 mm; no bleeding upon probing (BOP); no evidence of active clinical attachment loss, no evidence of radiographic alveolar bone loss, and ≥ 4 mm attached keratinized gingiva. Subjects with Stage III, Grade B Periodontitis presented with ≥ 4 teeth with ≥ 6 mm PD, ≥ 5 mm clinical attachment loss, radiographic alveolar bone loss extending to the middle third of root and beyond, and ≥ 4 mm attached keratinized gingiva as we previously described [35, 36]. All examinations were performed with a manual periodontal probe (PCPUNC-15; Hu‐Friedy) by three investigators (MT, JG, and KC), with a high inter-examiner correlation coefficient κ = 0.85. For the diseased group, two periodontally affected maxillary/mandibular premolars first and second molars were randomly selected for biopsy. Biopsies from selected teeth measured approximately 2 mm in width and 4 mm in length of buccal or lingual/palatal gingiva. The first gingival biopsy was obtained at baseline (pre-therapy), while a second biopsy was obtained 4–6 weeks after nonsurgical periodontal therapy (post-therapy; n = 10) consisting of scaling and root planing and patient education on oral hygiene measures. The second preselected biopsy site was distinct from the first gingival biopsy to eliminate the impact of immune cell infiltration due to healing of the previously excised tissue. For the control group, samples were derived from healthy gingival tissues normally discarded during routine surgical crown lengthening procedures of maxillary/mandibular premolars or 1st and 2nd molars. Stimulated saliva from healthy volunteers, and periodontitis patients before and after treatment were collected in 50 mL tube. Isolation of human and murine gingival single cells Using our previously published protocol [39], gingival tissues were incubated in collagenase IV (2 mg/mL) and DNase I (1 mg/mL) in PBS + 2% FBS for 1–2 h at 37 °C. Tissues were mechanically dissociated, incubated an additional 30 min, treated with EDTA (20 µL of 0.5 M) for 10 min, and filtered through a 70-µm strainer. Cells were centrifuged at 400 × g for 5 min, washed, resuspended in PBS + 2% FBS, counted, and stained for immunophenotyping. Isolation of human salivary single cells Saliva samples were diluted 1:10 in saliva dilution buffer (PBS containing 2% FBS and 0.5% paraformaldehyde), filtered through a 70-µm strainer, and centrifuged at 400 × g for 5 min. Pellets were washed 3–4 times in dilution buffer and stored at 4 °C. For flow cytometry, 100,000 cells/sample were stained and analyzed on a Cytek multiparametric cytometer. Mice C3H/HeJCrl mice (8 weeks old, male) 8-week-old male C3H/HeJCrl mice were used under an approved protocol from the University of Illinois Chicago Institutional Animal Care Committee (ACC #22–122). All procedures adhered to institutional guidelines for animal handling and welfare. Ligature-induced periodontitis model and brodalumab treatment Periodontitis was induced using the established ligature-induced periodontitis (LIP) model [40, 41], previously described by our group. A 6-0 silk ligature was placed bilaterally between the maxillary first and second molars in 8–12-week-old male C3H/HeJCrl mice under ketamine/xylazine anesthesia. Brodalumab (low dose: 5 mg/kg and high dose: 20 mg/kg) was injected interproximally into the gingiva using a microsyringe (30-gauge needle) immediately following ligature placement (day 0) and after other day thereafter every second day. Mice were allocated to four groups: no-ligature control, mock-treated ligature, Brodalumab 5 mg/kg, and Brodalumab 20 mg/kg. These groups were analyzed separately on day 4 and day 8 after ligation, with each time point consisting of an independent cohort of n = 5 mice per group. We also included the no-ligature group as a control (n = 5). In total, 40 animals were used in the study (4 groups × 2 time points × 5 mice). Mice were euthanized at day 4 or day 8 post-ligature placement (DPL), and gingival tissues and maxillary arches were collected for downstream analyses. Flow cytometry Single-cell suspensions collected at 4 and 8 DPL were stained using Zombie NIR and DAPI for viability and nucleated cell identification. Fluorochrome-conjugated monoclonal antibodies against CD11b (BioLegend, clone M1/70), CD45 (BD Biosciences, clone 30-F11), CD3 (Thermo Fisher, polyclonal), CD4 (clone GK1.5), and CD8 (clone BLR173J) were used. Cells were incubated with antibodies for 45 min at 4 °C in PBS + 1% BSA, washed, and analyzed on a CytoFLEX cytometer (Beckman Coulter). A minimum of 50,000 events/sample was acquired. Unstained and isotype controls were included. Data were analyzed using FlowJo v10.9.0. Quantitative RT-PCR Total RNA was isolated from gingival tissues (50–100 mg) using the RNeasy Mini Kit (Qiagen). cDNA was synthesized from 500 ng of RNA using the First Strand cDNA Synthesis Kit (Thermo Scientific). Gene expression of IL-17A, IL-17RA, IL-17RB, IL-6, and TNFα was quantified using SYBR-based qPCR on a StepOnePlus thermocycler (Applied Biosystems). β-actin served as the housekeeping gene. Relative expression was calculated using the 2−ΔΔCt method and reported as mean ± SD. Micro-computed tomography (Micro-CT) Following removal of the gingival tissue, the maxilla was divided into two separate arches and fixed in 10% formaldehyde before micro-CT imaging (Scanco µCT40). This analysis was used to assess bone microarchitecture, including bone volume fraction, trabecular number, trabecular thickness, trabecular separation, and structure model index. The specimens were immersed in 70% ethanol and scanned at 70 kVp, 114 µA, 300 ms integration time, with a 10 μm voxel size. For 3D reconstruction and analysis, the threshold was set at 200–1000 Scanco units. The volume of interest was established by locating the medial-most slice and contouring 7 slices proximally and 8 slices distally, with the first and second maxillary molars (M1 and M2) selected as the region of interest (ROI). The ROI was defined within the interdental alveolar bone surrounding the molar teeth, using the cemento-enamel junction (CEJ) and alveolar bone crest (ABC) as anatomical landmarks [42]. Alveolar bone loss was quantified by standardized CEJ–ABC measurements following established microCT protocols for experimental periodontitis [42]. Specifically, the CEJ–ABC distance at the distal buccal roots of the first (M1) and second (M2) molars was measured in triplicate and averaged for analysis. Statistical analysis Data were analyzed using GraphPad Prism (GraphPad Software). Results are presented as mean ± SD or SEM. Comparisons between two groups were performed using Student’s t-test; multiple-group comparisons used one-way ANOVA. Statistical significance was defined as p < 0.05. Results Gingiva and saliva from PD patients showed increased CD4+IL-17+ cells with disease progression The study included 20 unique individuals, with longitudinal sampling in the periodontitis cohort generating 30 total biological specimens across three groups - Controls (n = 10), Periodontal Disease (PD, n = 10), and post–nonsurgical periodontal therapy (NSPT, n = 10) (Table 1). Subject demographics were comparable between groups: age did not differ significantly (Controls 48 ± 12.43 vs. PD 51 ± 10.53 years; n.s.), and sex distribution was also similar (Controls 5M/5F vs. PD 6M/4F; n.s.) (Table 1). Clinically, baseline PD subjects showed significantly greater disease activity than controls, including higher mean PPD (4.3 ± 0.9 vs. 2.5 ± 0.4 mm; p < 0.001), higher % plaque/calculus (85% vs. 10%; p < 0.0001), and higher % BOP (80% vs. 10%; p < 0.0001). Following NSPT, clinical indices improved significantly relative to PD baseline, with mean PPD decreasing to 3.2 ± 0.7 mm (p < 0.01), with % plaque/calculus decreasing to 20% and % BOP decreasing to 20% % (p < 0.001), supporting the clinical efficacy of NSPT (Table 1). Table 1Subject demographics and clinical parametersPatient VariablesControls(n = 10)Periodontal Disease [PD](n = 10)Nonsurgical Periodontal Therapy [NSPT] (n = 10)P-valueAge (years)48 ± 12.4351 ± 10.53-n.sGender (M/F)5/56/4-n.sMean PPD (mm)2.5 ± 0.44.3 ± 0.93.2 ± 0.7< 0.001 (Control)*<0.01 (NSPT)% Plaque/Calc8%85%15%< 0.0001 (Control)*<0.001 (NSPT)% BOP8%80%20%< 0.0001 (Control)*<0.001 (NSPT) Subject demographics and clinical parameters < 0.001 (Control) *<0.01 (NSPT) < 0.0001 (Control) *<0.001 (NSPT) < 0.0001 (Control) *<0.001 (NSPT) To assess whether Th17 cells are associated with periodontitis (PD), we first compared the frequency of CD4⁺IL‑17⁺ T cells in gingival tissues from periodontally healthy and diseased subjects. Inflamed gingiva showed a markedly higher proportion of CD4⁺IL‑17⁺ cells (13.10 ± 2.25%; p < 0.0001) than healthy tissues (2.78 ± 1.28%) (Fig. 1A, B). Saliva provides a non-invasive, easily repeatable specimen for longitudinal monitoring that samples inflammatory cells and mediators shed from periodontal tissue. Therefore, we next evaluated whether salivary immune profiling recapitulates gingival Th17-associated changes. Consistent with the gingival findings, saliva from periodontitis patients contained significantly more CD4⁺IL‑17⁺ cells (15.94 ± 3.37%; p < 0.0001) than saliva from healthy controls (5.30 ± 0.83%) (Fig. 1C). Notably, non-surgical periodontal therapy was associated with reduced disease activity and a corresponding decline in CD4⁺IL‑17⁺ T cells in both gingiva (6.68 ± 2.43%; p < 0.01) and saliva (9.60 ± 3.43%; p < 0.001) (Fig. 1D). Gingiva and saliva from periodontitis patients show increased CD4⁺IL-17⁺ cells with disease progression and partial normalization after therapy. (A) Gating strategy demonstrating CD4⁺IL-17⁺ T cells identified among CD45⁺ lymphocytes in human gingival samples. Representative contour plots from a periodontally healthy subject, and a PD patient and, from the same PD patient after NSPT, illustrating the frequency of CD4⁺IL-17⁺ T cells in gingival tissue (percentages indicated in red). (B) Quantification of gingival CD4⁺IL-17⁺ T cells from healthy, PD, and NSPT groups. Diseased gingiva shows a marked expansion of CD4⁺IL-17⁺ cells compared with healthy tissue, with a partial reduction toward baseline after therapy. (C) Representative flow cytometry plots depicting CD4⁺IL-17⁺ T cells in saliva from healthy, PD, and NSPT subjects. (E) Grouped data for salivary CD4⁺IL-17⁺ T-cell frequencies, demonstrating significantly elevated proportions in PD compared with healthy saliva and a decrease after therapy. (F) Total RNA was isolated from the gingival biopsies from healthy and PD patients. Expression of IL-17A, IL-6 and TNF-α transcripts was quantified by RT-qPCR. (G) Total RNA was isolated from gingival biopsies of an independent cohort of healthy subjects and PD patients before and after nonsurgical periodontal therapy to assess the impact of treatment on IL-17 signaling. Transcript levels of IL-17 A, IL-6 and TNF-α were quantified by RT-qPCR to evaluate changes in inflammatory signaling associated with treatment. Bars represent mean ± SEM; each dot represents an individual subject. Statistical significance between groups was determined using ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001) To further confirm that clinical inflammation is linked to increased IL-17 pathway activity, we analyzed gingival biopsies by RT-qPCR. Compared with healthy gingiva, periodontally diseased tissues showed significantly increased expression of IL-17–associated inflammatory genes, including IL1-7A (8.7-fold; p < 0.003), IL-6 (4.6-fold; p < 0.01), and TNFα (2.1-fold; p < 0.01) (Fig. 1E). To examine whether the IL-17 pathway is responsive to periodontal therapy, we analyzed IL-17A, IL-6, and TNFα expression in an independent cohort of periodontitis patients before and after treatment. Relative to healthy gingiva, periodontally diseased tissues exhibited increased expression of IL-17A (6.7-fold), IL-6 (1.9-fold), and TNFα (3.1-fold). Following therapy, expression levels were reduced, with IL-17A decreasing to 2.6-fold, IL-6 to 0.8-fold, and TNFα to 0.9-fold relative to healthy controls, consistent with attenuation of inflammatory signaling after treatment (Fig. 1F). These data indicate activation of an IL-17–skewed inflammatory program in human periodontitis, consistent with the immune profiling of gingival infiltrates revealing a clear expansion of CD4⁺IL‑17⁺ cells in periodontitis. Transcriptional upregulation of pro-inflammatory cytokines and elevated IL-17 in PD reflect increased Th17 accumulation. Collectively, these findings support a key role for Th17 cells in periodontitis and highlight the IL-17 axis as a potential biomarker and therapeutic target. Brodalumab treatment attenuates IL‑17–associated inflammatory signaling in a murine model of periodontitis IL‑17 signaling is a central driver of periodontal inflammation and cytokine amplification [23, 24]; therefore, we tested whether brodalumab [37, 38] dampens this axis in a murine ligature-induced periodontitis (LIP) model (Fig. 2A). After LIP induction, mice received brodalumab at either a low dose (5 mg/kg) or high dose (20 mg/kg) to evaluate dose responsiveness and were analyzed at day 4 and day 8 post-treatment to capture early and later phases of inflammation. Gingival tissues were harvested at each time point and expression of Il17a and downstream mediators (Il1β, Il6, Tnfα) was quantified by RT-qPCR to determine whether brodalumab effects extend beyond target engagement. Brodalumab treatment suppresses IL-17 and other pro-inflammatory cytokines in ligature-induced periodontitis. (A) Schematic overview of the experimental timeline and sampling workflow. Mice were subjected to experimental periodontitis by placing a ligature between mandibular M1 and M2 molars. Brodalumab (5 mg/kg or 20 mg/kg) or mock vehicle was locally injected into the gingiva using microneedles every 48 h. Gingival tissues were harvested at the indicated acute (day 4) and later (day 8) time points for inflammatory profiling by RT-qPCR, flow cytometric and alveolar bone analysis. (B) Relative expression of il17a, il17b, il17ra, il17rb and canonical pro-inflammatory mediators il-1β, il-6, and tnf-α in brodalumab-treated animals relative to mock controls. Data are presented as relative gene expression normalized to housekeeping control GAPDH and expressed versus the indicated control group; points represent individual animals and bars indicate mean ± SEM. Statistical significance was calculated using ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001) Brodalumab-treated animals demonstrated marked suppression of Il17a, with significant inhibition evident by day 4 (5 mg/kg: 0.13-fold, p < 0.0001; 20 mg/kg: 0.02-fold, p < 0.0002) and, this suppression was sustained through day 8 (5 mg/kg: 0.05-fold, p < 0.0001; 20 mg/kg: 0.07-fold, p < 0.0001) relative to controls (Fig. 2B, left upper panel). These data demonstrate effective in vivo inhibition of the IL‑17 pathway by brodalumab. To assess broader effects of brodalumab treatment within the IL‑17 network, we also measured Il17b. In contrast to Il17a, Il17b showed minimal change at day 4 (5 mg/kg: 0.85-fold, p > 0.05; 20 mg/kg: 0.84-fold, p > 0.05), but was significantly reduced by day 8 (5 mg/kg: 0.13-fold, p < 0.0001; 20 mg/kg: 0.02-fold, p < 0.0002) (Fig. 2B, upper panel). To exclude the possibility that drug treatment modulates il17ra expression, we assessed gingival il17ra levels in brodalumab-treated and mock-treated animals. Our results showed that compared with mock, expression of il17ra or il17rb did not differ significantly at either time point in brodalumab-treated animals (Fig. 2B, upper panel), suggesting that the therapeutic effects observed are not driven by changes in receptor expression. Because IL‑17–mediated pathology often propagates through secondary inflammatory cascades [43, 44], we next evaluated downstream cytokines. Brodalumab reduced il1β (day 4 fold change: low dose: 0.9; high dose: 0.72; day 8 fold change: low dose: 0.52; high dose: 0.38), il6 (day 4 fold change: low dose: 0.12; high dose: 0.11; day 8 fold change: low dose: 0.2; high dose: 0.1), and tnfα (day 4 fold change: low dose: 0.55; high dose: 0.42; day 8 fold change: low dose: 0.66; high dose: 0.48) at both time points (Fig. 2B, lower panel), indicating early suppression of inflammatory activation that persists over time. Overall, these findings show that brodalumab not only suppresses the IL‑17 axis (il17a) but also concurrently dampens broader pro-inflammatory cytokine programs, supporting a dose-responsive, pathway-centered anti-inflammatory effect in experimental periodontitis. Brodalumab decreases gingival CD4⁺IL-17⁺ T cells while increasing CD4⁺IL‑10⁺ regulatory T-cell frequencies IL‑17–driven CD4⁺ T cell responses are a key driver of periodontal pathogenesis [23, 24], while IL‑10–producing CD4⁺ regulatory populations counteract excessive tissue-damaging immunity [45, 46]. To assess the gingival immune profiles of these immune subsets, we used flow cytometry to determine whether brodalumab shifts the gingival immune infiltrate toward a more immunoregulatory profile in the LIP model. Animals subjected to LIP were treated with brodalumab at 5 mg/kg or 20 mg/kg, and gingivalgingival IL17⁺ and IL‑10⁺ CD4 T cell subsets were quantified by flow cytometry (Fig. 3A-C). Brodalumab treatment significantly decreased the frequency of CD4⁺IL‑17⁺ T cells in gingival tissue compared with LIP controls, with more pronounced reduction observed at the higher dose, supporting a dose-dependent suppression of the pro-inflammatory IL‑17 compartment. Compared to mock, brodalumab-treated animals showed lower CD4⁺IL-17⁺ T cells at both early (5 mg/kg: 3.3-fold; *p < 0.01 and 20 mg/kg: 2.8-fold; *p < 0.02) and late time points (5 mg/kg: 8.3-fold; *p < 0.03 and 20 mg/kg: 2.7-fold; *p < 0.002)(Fig. 3E). Brodalumab-treated gingiva showed a reduction in CD4⁺IL-17⁺ T cells accompanied by an increase in CD4+ IL-10+ T-cell population. Animals subjected to ligature-induced periodontitis (LIP) were treated by local gingival injection of brodalumab (5 or 20 mg/kg) or mock vehicle, with a no-ligature group included as a baseline control. Gingival leukocytes were harvested and analyzed by flow cytometry to quantify inflammatory and immunoregulatory CD4⁺ cells. Representative scatter plots show the (A) CD4⁺ T cells from gingival leukocytes, and intracellular cytokine staining to identify (B) CD4⁺IL-17⁺ cells and (C) CD4⁺IL-10⁺ cells across experimental groups (no ligature, mock, 5 mg/kg brodalumab, and 20 mg/kg brodalumab). Bar graphs showing (D) CD4⁺IL-17⁺ T cells and (E) CD4⁺IL-17⁺ T-cell frequencies in different groups. Data are presented as mean ± SEM. Statistical significance was assessed by one-way ANOVA with significance denoted as * p < 0.05, ** p < 0.01, *** p < 0.001 In parallel, brodalumab treatment concomitantly increased the proportion of CD4⁺IL‑10⁺ cells (Day 4: 5 mg/kg: 5.35-fold; *p < 0.05 and 20 mg/kg: 6.9-fold; *p < 0.05; Day 8: 5 mg/kg: 13.15-fold; *p < 0.03 and 20 mg/kg: 21-fold; *p < 0.02) compared to mock, consistent with induction of an immunosuppressive or regulatory T-cell phenotype within the gingival infiltrate (Fig. 3D). Collectively, these findings indicate that brodalumab not only dampens inflammatory T cell accumulation but also drives resolution, actively restoring local CD4⁺ T-cell response by reducing pathogenic IL‑17–producing cells while increasing IL‑10–associated regulatory populations in gingiva. Brodalumab treatment restricts gingival neutrophil infiltration and promotes M2-like Mφ skewing and pro-resolution gene expression Resolution of periodontal inflammation is increasingly understood as an active, coordinated program driven by multiple cellular and molecular drivers [40, 46, 47]. In periodontal tissues, successful resolution is typically characterized by reduced neutrophil accumulation, a shift in macrophage activity toward M2-like reparative phenotypes, and induction of pro-resolving pathways that support clearance of inflammation and restoration of tissue homeostasis [10, 40, 47]. To determine whether IL-17RA blockade remodels the innate immune landscape in ligature-induced periodontitis, we quantified gingival myeloid populations and assessed transcriptional markers associated with inflammatory resolution. Consistent with a dampened IL-17–driven inflammatory program, brodalumab treatment significantly restricted gingival accumulation of neutrophils as observed by reduced frequencies of Ly6G⁺CD11b⁺ cells (5 mg/kg: 20.43 ± 3.44; 20 mg/kg: 10.1 ± 1.50; p < 0.05) compared with mock controls (31.26 ± 1.97) (Fig. 4A-B). This reduction in infiltrating neutrophils suggests that brodalumab limits the chemokine and cytokine cues that normally sustain neutrophil-rich inflammation during active periodontal breakdown. Brodalumab dampens gingival myeloid inflammation and enhances resolution-associated pathways. Mice were subjected to ligature-induced periodontitis (LIP) and treated by local gingival injection of the IL-17RA inhibitor brodalumab at a low (5 mg/kg) or high (20 mg/kg) dose, or mock vehicle. Gingival tissues were harvested at the indicated time points (day 4 and day 8, where shown), processed into single-cell suspensions for flow cytometry, and separately analyzed for gene expression by RT-qPCR. (A) Single cells were gated and CD45⁺ leukocytes were identified, followed by gating on CD11b⁺ myeloid cells. Representative scatter plots showing CD11b⁺Ly6G⁺ neutrophils in different groups. (B) Bar graphs show the percentage of CD11b⁺Ly6G⁺ neutrophils in gingival tissues from mock- and brodalumab-treated animals. Macrophages were identified within the CD11b⁺ compartment (CD68⁺ tissue macrophages, as shown) and assessed for polarization status. Representative overlaid histograms and scatter plots depict brodalumab-associated shifts in (C, D) CD163 expression (M2-like) and (F, G) CD32 expression (M1-like) on gingival macrophages. (E) Quantification of CD11b⁺CD163⁺ M2-like macrophages and (H) quantification of CD11b⁺CD32⁺ M1-like macrophages in mock- and brodalumab-treated groups. Gingival tissues were further analyzed by RT-qPCR for expression of lipoxygenase genes involved in pro-resolving lipid mediator biosynthesis. Brodalumab treatment increased expression of (I) alox5, (J) alox12, and (K) alox15 at the indicated time points. Data are presented as mean ± SEM. Statistical significance is indicated using standard notation (*p < 0.05, **p < 0.01, ***p < 0.001) and was determined by ANOVA with appropriate post hoc testing Importantly, brodalumab treatment skewed macrophage polarization within gingival tissues. Flow cytometric analysis showed a clear induction of M2-like markers and suppression of M1-like markers on CD68⁺ tissue macrophages, as demonstrated by the overlaid histograms and scatter plots (Fig. 4C–D, F–G). Consistent with this, brodalumab promoted an M2-like macrophage phenotype, reflected by an increase in CD11b⁺CD163⁺ macrophages (9.1 ± 1.37 and 20.46 ± 2.10 vs. mock: 4.90 ± 0.17; p < 0.05), while concomitantly reducing CD11b⁺CD32⁺ M1-like macrophages (19.33 ± 1.10 and 10.9 ± 1.73 vs. mock: 28.76 ± 3.12; p < 0.05) (Fig. 4E, H). Together, these data indicate that brodalumab not only dampens inflammation but also reprograms the local innate immune compartment away from a pro-inflammatory state and toward a phenotype consistent with tissue repair and resolution. To further test whether this cellular shift correlates with activation of resolution pathways, we examined the expression of Arachidonate Lipoxygenases (alox), key enzymes involved in the generation of pro-resolving lipid mediators [48, 49]. Compared with mock, day 8 brodalumab-treated gingival tissues showed a dose-dependent increase in expression of alox5 (low dose: 1.4-fold; high dose: 2.4-fold; p < 0.05), alox12 (low dose: 2.33-fold; high dose: 6.95-fold; p < 0.05), and alox15 (low dose: 1.7-fold; high dose: 3.6-fold; p < 0.05) (Fig. 4I–K). At day 4, alox15 (low dose: 1.9-fold; high dose: 2.7-fold; p < 0.05) showed significant induction, while alox12 levels showed modest upregulation at higher dose (high dose: 1.7-fold; p < 0.05) in brodaluma-treated animals (Fig. 4J, K). The concordance between reduced neutrophil/monocyte infiltration, enrichment of M2-like macrophages, and induction of alox5, alox12 and alox15 supports a model in which IL-17RA blockade facilitates a transition from sustained inflammatory recruitment to an active pro-resolution program. Collectively, these results indicate that brodalumab limits myeloid inflammatory infiltration, a key pathological feature of ligature-induced periodontitis, while simultaneously promoting macrophage polarization and gene expression programs associated with resolution, providing a mechanistic link between IL-17RA targeting and reduced periodontal inflammatory burden. Brodalumab prevents ligature-induced alveolar bone loss and limits disease progression To determine whether local brodalumab delivery can protect against periodontitis-associated bone destruction, experimental periodontitis was induced by ligature placement (LIP) and mice received localized gingival injections of brodalumab at 5 mg/kg or 20 mg/kg, and the readouts were evaluated on day 4 and day 8 post-ligature. Brodalumab-treated animals displayed preservation of alveolar bone architecture, most prominently in the 20 mg/kg group. Representative 3D microCT reconstructions show that mock-injected ligated mice developed clear alveolar bone loss characterized by an increased distance between the cementoenamel junction (CEJ) and the alveolar bone crest (ABC), consistent with progressive periodontal destruction (Fig. 5A). Quantification of bone loss confirmed that brodalumab treatment [M1B (Day 4: 5 mg/kg: 18.57 μm; *p = n.s. and 20 mg/kg: 13.52 μm; *p < 0.03; Day 8: 5 mg/kg: 20.74 μm; *p < n.s. and 20 mg/kg: 17.83 μm; *p < 0.03); M2: Day 4: 5 mg/kg: 10.84 μm; *p < n.s. and 20 mg/kg: 9.80 μm; *p < n.s.; Day 8: 5 mg/kg: 10.72 μm; *p < 0.01 and 20 mg/kg: 8.5 μm; *p < 0.01) significantly reduced the CEJ–ABC distance compared with mock-treated ligated controls [M1B (Day 4: 19.75 μm; Day 8: 22 μm); M2 (Day 4: 11.42 μm; Day 8: 17.5 μm)] at both day 4 and day 8, demonstrating protection from LIP-driven bone resorption (Fig. 5B). Importantly, by day 8, the 20 mg/kg brodalumab group exhibited CEJ–ABC distances that approximated the no-ligature baseline, while mock-injected animals showed a markedly increased CEJ–ABC distance indicative of severe disease, suggesting that brodalumab effectively prevents alveolar bone loss and slows disease progression in this murine model. Brodalumab-treated animals subjected to LIP exhibit superior bone volume and bone mineral density. Experimental periodontitis was induced by ligature (LIP) and animals received local gingival injection of brodalumab (5 or 20 mg/kg) at the ligated site after every 48 h. Mice were euthanized at day 4 or day 8 after injection, and maxillae were analyzed by micro-CT. (A) Representative 3D reconstructed microCT images of the maxillary molar region for each group, with red arrows indicating the cementoenamel junction (CEJ)–to–alveolar bone crest (ABC) distance and illustrating marked bone loss in mock-treated ligated sites compared with no-ligature controls. (B) Quantification of CEJ–ABC distance (in µm) in brodalumab-treated animals shows retention of alveolar bone height and less crestal bone resorption at both time points compared to the mock, particularly at 20 mg/kg. Bar graphs depict (C) bone volume (BV), (D) bone mineral density (BMD), (E) trabecular number (in %) and (F) trabecular thickness (in µm) on day 4 and day 8 across all four groups. Data are presented as mean ± SEM; statistical significance between groups was assessed by ANOVA with appropriate post hoc tests, with significance levels indicated in the figure (*p < 0.05, **p < 0.01, ***p < 0.001) Next, we examined the impact of brodalumab on bone quality. Mock-treated animals exhibited the expected loss of bone quality, reflected by reduced bone volume and reduced bone mineral density relative to no-ligature controls (Fig. 5C, D). In contrast, brodalumab-treated animals showed superior bone volume (Day 4: 5 mg/kg: 54.79%; *p < n.s. and 20 mg/kg: 69.30%; *p < 0.005) and higher bone mineral density (Day 4: 5 mg/kg: 602.26%; *p < n.s. and 20 mg/kg: 755.20%; *p < 0.004) compared with mock-treated (51.83% and 573.83%, respectively) animals in a dose-dependent manner. The osteoprotective effect of brodalumab was more evident by day 8, where values in the high-dose group approached those observed in the no-ligature condition [Bone volume (Day 8: 5 mg/kg: 48.68%; *p < 0.05 and 20 mg/kg: 67.87%; *p < 0.005) and bone mineral density (Day 8: 5 mg/kg: 469.54%; *p < 0.05 and 20 mg/kg: 736.30%; *p < 0.004) compared with mock-treated (39.37% and 422.62%, respectively) (Fig. 5C, D). To evaluate changes in bone microarchitecture, we quantified trabecular number (Tb.N) and trabecular thickness (Tb.Th), as reductions in these parameters reflect trabecular deterioration, whereas their preservation indicates protection against inflammation-driven bone resorption. For ROI M1, high-dose brodalumab significantly increased Tb.N (in %) at both time points (day 4: 32.88; day 8: 33.97; p < 0.05) compared with mock-treated controls (day 4: 29.04; day 8: 31.9), indicating improved preservation of bone microarchitecture (Fig. 5E). A similar effect was observed at ROI M2, with a significantly higher Tb.N (in %) at the high dose on day 4 (37.31 vs. 30.0 [mock]) but not on day 8 (30.96 vs. 30.10 [mock]). In contrast, low-dose treatment did not produce significant changes at either site. Trabecular thickness also increased with high-dose brodalumab on day 4, with significant increases at both M1 (4.8 μm) and M2 (5.3 μm) compared with mock-treated controls (4.1 μm [M1]; 4.7 μm [M2]) (Fig. 5F). Overall, these findings indicate that brodalumab treatment, particularly at 20 mg/kg, limits ligature-induced periodontitis–driven bone loss and preserves bone integrity, as measured by microCT-derived bone volume, mineral density, and microarchitectural parameters. Discussion Periodontitis is sustained by a self-amplifying inflammatory network in which leukocyte recruitment, epithelial activation, and osteoclastogenic signaling reinforce one another and ultimately drive connective tissue breakdown and alveolar bone loss [1–5, 50]. Uncontrolled proinflammatory cytokine signaling acts in a cooperative manner to sustain chronic inflammation. Pharmacologic inhibition of key inflammatory pathways, including the NLRP3 inflammasome, IL‑1β, and TNF‑α signaling axes, has been shown to suppress osteoclastogenesis and mitigate alveolar bone loss in experimental periodontitis, underscoring the therapeutic potential of host-modulatory approaches to inhibit periodontal inflammation [11–14]. These findings provide a broader rationale for evaluating other inflammatory signaling nodes involved in periodontal tissue destruction. In this context, the IL-17 pathway is of particular interest because it links inflammatory activation to osteoclastogenic responses and alveolar bone remodeling. Consistent with the immune profiling of gingival infiltrates revealing a clear expansion of CD4⁺IL-17⁺ T cells in periodontitis, transcriptional upregulation of pro-inflammatory cytokines and elevated IL-17 in PD reflect increased Th17 accumulation. These findings support a key role for Th17 cells in periodontitis and highlight the IL-17 axis as a potential biomarker and therapeutic target. Recent studies highlight the importance of suppressing IL-17 in PD to limit inflammatory progression and preserve periodontal tissues [51–53]. Targeting cytokine receptor signaling can effectively dampen pro-inflammatory cytokine networks that drive tissue destruction. Specifically, a recent report showed that IL-17 activity can be curtailed indirectly by modulating the tightly linked IL-1–IL-17 axis [54, 55]. Previous studies have demonstrated that IL-1 receptor signaling can be inhibited by targeting IL-1 receptor antagonist pathway. IL-1RA, a member of the IL-1 superfamily, suppresses inflammation by competitively binding IL-1 receptors and thereby reducing IL-1α and IL-1β activity without initiating downstream signaling. Additionally, the functional link between IL-1 signaling and IL-17 production is supported by studies in Il1ra knockout (Il1ra−/−) mice, which develop multiple inflammatory phenotypes, including arthritis, psoriasis, and encephalomyelitis [55, 56]. Mechanistically, IL-17 reporter systems have shown that Vγ6 + CCR2 + γδ T cells are a preferential IL-17 source in inflamed tissues. Because IL-1RA normally restrains IL-1R expression on γδ T cells, IL-1RA deficiency increases IL-1R expression on Vγ6 + cells, promoting IL-17 production by these TCR-specific lymphocytes [55, 56]. Brodalumab, a targeted immunotherapy against IL-17R signaling, exhibits robust inhibition of both mucosal inflammation and osseous damage in psoriasis [37, 38]. This is a particularly distinct therapeutic approach because blocking IL-17RA interrupts signaling from multiple IL-17 family ligands that converge on this receptor, rather than neutralizing a single cytokine. In a disease characterized by cytokine redundancy and compensatory inflammatory loops, IL-17R targeting offers a broader and potentially more durable and robust strategy at a key inflammatory node. Direct targeting of the IL-17 pathway in LIP models further supports the therapeutic relevance of this axis. For example, intraperitoneal administration of secukinumab (Cosentyx) in a rat LIP study significantly reduced IL-17 levels, alveolar bone loss, gingival inflammatory infiltrate, and improved osteoimmune remodeling indices, including the RANKL/osteoprotegerin ratio [58]. Together, these studies reinforce the concept that the IL-17 axis is not merely a marker of disease severity but a driver of bone-destructive inflammation, and that interrupting this pathway can alter disease trajectory. Our results align with, and extend, these observations by demonstrating that direct IL-17RA blockade via local brodalumab delivery is associated with both structural and immunologic improvement of periodontal tissues. MicroCT analysis showed an early reversal of bone loss, with measurable improvements in alveolar bone volume and density beginning as early as day 4 after ligature placement and persisting through day 8. This timing is consistent with the concept that IL-17 acts as an early amplifier of periodontal inflammation and that early pathway interruption can shift downstream osteoimmune outcomes. IL-17 expression is also shaped by counter-regulatory cytokines, particularly IL-10. A recent study demonstrated that IL-17 levels are significantly associated with periodontal disease and are inversely related to IL-10 [59]. IL-10 limits IL-17–amplified inflammatory programs by suppressing chemokines such as CXCL5 and CXCL1 [59], which otherwise promote the pro-inflammatory activation of circulating monocytes and monocyte-derived Mφ. In both P. gingivalis–induced murine periodontitis and ligature-induced alveolar bone-loss models, Il10-deficient mice exhibited increased bone loss and elevated Il17 transcripts alongside IL-17–dependent chemokine and cytokine expression [59, 60]. Importantly, the restraining effect of IL-10 on IL-17 signaling appeared to be mediated primarily through innate immune cell populations rather than gingival epithelial cells, despite epithelial cells being major IL-17 targets [59]. Excessive IL-17 signaling also promoted an M1-skewed Mφ phenotype in gingiva, exacerbating bone loss progression observed in the ligature model [60, 61]. Consistent with this, our immune profiling data in LIP model demonstrate that brodalumab-driven IL-17RA blockade produces an immunosuppressive, tolerance-favoring shift. Specifically, treatment reduced IL-17A and IL-17B along with key pro-inflammatory cytokines including IL-1β, IL-4, and TNF-α, beginning at day 4 and continuing through day 8. This pattern suggests coordinated changes in lymphocyte differentiation and effector balance, potentially reflecting increased suppressive activity and reduced CD4+ skewing towards Th17-associated IL-17A production. In parallel, IL-10 increased significantly from day 4 through day 8, consistent with a regulatory immune trajectory that may involve CD4+ differentiation toward CD25⁺FoxP3+ Treg lineages. Resolution of periodontal inflammation is typically marked by a lower neutrophil and monocyte burden and activation, reflecting restoration of barrier homeostasis and reduced chemotactic drive. Brodalumab-treated animals exhibited significantly reduced Ly6G⁺CD11b⁺ myeloid population, suggesting dampened neutrophil accumulation and inflammatory monocyte recruitment. Importantly, brodalumab treatment skewed myeloid phenotype by promoting CD163 + CD68+ M2-like Mφ while suppressing HLA‑DR⁺CD32⁺ M1-like Mφ, supporting a shift toward a reparative, pro-resolving phenotype. This Mφ polarization is particularly relevant in periodontitis, where persistent inflammatory Mφ activation can sustain osteoclastogenic cues and tissue breakdown, while pro-resolving Mφ states support clearance of inflammation and tissue repair [17]. M2-like Mφ contribute to resolution biology, including efferocytosis and the generation and handling of specialized pro-resolving mediators that actively terminate inflammation [10, 62]. In line with this, increased expression of alox5 and alox15 in brodalumab-treated tissues further supports engagement of lipid mediator pathways linked to resolution [63]. We and others have previously demonstrated higher gingival infiltration of M1-like Mφ in periodontitis subjects, while nonsurgical periodontal therapy (NSPT) shifts Mφ polarization from M1- to M2-like Mφ, consistent with treatment-associated resolution and restoration of tissue homeostasis [40, 63, 64]. Overall, these coordinated changes would be expected to reduce leukocyte recruitment signals, dampen inflammatory activation states, and mitigate continued osteoclastogenic signaling driving alveolar bone loss [65]. Our study differs from earlier IL-17–targeting reports in several important respects. First, rather than neutralizing IL-17A alone, we targeted IL-17RA with brodalumab. This is a key mechanistic distinction because IL-17RA serves as a shared receptor subunit for multiple IL-17 family cytokines, allowing receptor blockade to modulate a broader inflammatory signaling network than ligand-specific inhibition alone [54–60]. Second, unlike approaches directed against a single IL-17 cytokine axis, IL-17R blockade influenced multiple IL-17-related and downstream inflammatory mediators, including IL-17A/B, IL-6, and TNF-α [66]. These observations suggest that receptor-level targeting may more effectively suppress the integrated and potentially redundant inflammatory circuitry that drives periodontal tissue destruction. Third, whereas previous human studies largely provided indirect clinical observations by evaluating periodontal status in patients receiving IL-17–directed biologics for dermatologic disease [37, 38], our work directly tested IL-17R blockade in a ligature-induced periodontitis model and linked this intervention to both reduced periodontal inflammation and protection against alveolar bone loss and correlates these findings with observations in subjects with PD before and after periodontal therapy. Collectively, these distinctions support IL-17RA as a mechanistically broader and potentially more translationally relevant host-modulatory target in periodontal disease. Gingiva is an immunologically active barrier site where physiological levels of IL-17 can contribute to antimicrobial defense, epithelial integrity, and neutrophil-mediated surveillance [67]. Conversely, exaggerated or prolonged IL-17 responses can drive tissue injury, particularly by sustaining neutrophilic inflammation and amplifying inflammatory cytokine networks. Our data suggest potential targeting and modulation of IL-17R pathway in patients with prolonged and severe inflammation despite conventional therapy, high neutrophilic activity, IL-17–signature biomarkers, or systemic inflammatory comorbidities where IL-17–driven pathways are already implicated. Importantly, the observed reduction in IL‑17⁺CD4⁺ cells after NSPT underscores that host modulation might be most effective as an adjunct rather than a replacement, targeting the inflammatory amplification loops that remain even after bacterial load reduction. Salivary immune profiling demonstrated in this study can provide longitudinal assessment of IL‑17⁺CD4⁺ cells burden to identify appropriate patients. However, translation to periodontal practice would likely require careful dose, route, and patient-selection considerations. As mentioned above, IL-17 is important in mucosal host defense, especially against fungal pathogens, and systemic IL-17 blockade in other disease settings has been associated with mucocutaneous candidiasis risk in some patients [63, 64]. Localized drug delivery approach, demonstrated in this study, could be adopted to modulate IL-17R to mitigate periodontal inflammation while minimizing systemic immune compromise. Conclusion Our findings suggest that IL-17RA targeting is a uniquely strategic intervention in periodontitis because it blocks a pivotal receptor-level hub that integrates IL-17 family inflammatory signals, dampens the IL-1–IL-17 amplification loop, and promotes a regulatory, IL-10–associated immune milieu. This coordinated immunomodulation provides a plausible explanation for the concurrent reduction in inflammatory mediators, induction of pro-resolving immune subsets, and the early, measurable preservation and recovery of alveolar bone architecture observed in our model. Collectively, these data suggest that brodalumab, as an IL-17RA inhibitor, may serve as a promising adjunct to periodontal therapy by selectively suppressing IL-17–driven inflammatory signaling and limiting downstream tissue destruction. Electronic Supplementary Material Below is the link to the electronic supplementary material.